TPD & Induced Proximity Summit Leaderboard
  • Saturday, June 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 32

Author

Pharma Journalist 8887 posts 0 comments

China Approves ENHERTU for Second-Line HER2-Positive Gastric Cancer

Jan 23, 2026
China’s National Medical Products Administration (NMPA) has approved ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic…
Read More...

Insilico and Hygtia Partner to Advance AI-Discovered NLRP3 Inhibitor

Jan 22, 2026
Insilico Medicine and Hygtia Therapeutics have entered into an exclusive global license and co-development agreement to advance ISM8969, an investigational NLRP3 inhibitor designed for…
Read More...

Wugen’s Sofi-cel Secures FDA Breakthrough Status in T-ALL/LBL

Jan 22, 2026
Wugen has received a major regulatory endorsement from the U.S. Food and Drug Administration, which has granted Breakthrough Therapy Designation to its investigational CAR-T cell…
Read More...

Charles River and Gazi University Partner on Gene Therapy Development

Jan 22, 2026
Charles River Laboratories International and Gazi University Faculty of Medicine have entered into a strategic collaboration aimed at advancing gene therapy research for rare genetic…
Read More...

NEOK Bio Wins FDA IND Clearance for Bispecific ADC NEOK001

Jan 22, 2026
NEOK Bio has taken a key step toward clinical development after the U.S. Food and Drug Administration approved its Investigational New Drug application for NEOK001, clearing the way for…
Read More...

Opna Bio’s Zavabresib Wins FDA Orphan Status in Myelofibrosis

Jan 22, 2026
Opna Bio, a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, has received a key regulatory boost for its myelofibrosis program. The U.S. Food and…
Read More...

Novo Nordisk and Aspect Deepen Cell Therapy Alliance in Diabetes

Jan 22, 2026
Novo Nordisk and Aspect Biosystems have announced the expansion of their strategic partnership, entering a new phase focused on developing advanced cellular medicines for diabetes that…
Read More...

BMS and Microsoft Partner to Advance AI-Based Lung Cancer Detection

Jan 22, 2026
Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Microsoft to accelerate the early detection of lung cancer by integrating advanced artificial intelligence…
Read More...

Shionogi Expands Stake in ViiV Healthcare After Pfizer Exit

Jan 22, 2026
GSK plc and Japan-based pharmaceutical company Shionogi & Co., Ltd. have reached an agreement, alongside Pfizer Inc., to reshape the ownership structure of ViiV Healthcare, the…
Read More...

AstraZeneca Secures Full Global Rights to AbelZeta’s C-CAR031

Jan 21, 2026
AstraZeneca has agreed to acquire AbelZeta Pharma’s remaining stake in the China development and commercialization rights to C-CAR031, consolidating full global control of the…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.